A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of RC48-ADC for injection in subjects with
advanced non-small cell lung cancer with HER2 overexpression or HER2 mutation.